Theodore H. Schwartz

Theodore H. Schwartz


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2025 in Journal of Neurosurgery
Verified
Journal Article
Closed access
PDF file
EBEvan D. Bander
Evan D. Bander
APAbhinav Pandey
Abhinav Pandey
CGCarson Gundlach
Carson Gundlach
YLYing Li
Ying Li
MLMiguel Tusa Lavieri
Miguel Tusa Lavieri
TSTheodore H. Schwartz
Theodore H. Schwartz
OBJECTIVE: Resection of nonfunctional pituitary adenomas (NFPAs) can precipitate transient, or in some cases, permanent hormone deficits requiring replacement. Predicting the risk of permanent hormone dysfunction and the possibility of improvement postsurgery is crucial for patient counseling. This study analyzed a large cohort of patients with NFPA to assess predictors of postoperative hormone function and to help both surgeons and patients better predict outcomes. METHODS: The authors conducted a retrospective single-institution study on a series of patients treated for NFPAs at Weill Cornell Medicine between 2006 and 2023. Data including demographics, preoperative hormone status, laboratory values, pathological and radiographic tumor characteristics, and postoperative transient and permanent hormone replacement were collected. Multivariable logistic regression analysis was used to identify predictors of hormone deterioration and improvement. RESULTS: A cohort of 372 patients were included in this study, 56% of whom presented with preoperative hormone deficiency of at least one axis. A total of 79% of patients underwent gross-total or near-total resection. Postoperatively, 178 (48%) required permanent hormone replacement for at least one hormonal axis: thyroid (34%), cortisol (23%), gonadotropin (15%), and antidiuretic hormone (7%). In patients with no preoperative endocrinopathy, 30.8% needed new hormone replacement therapy. Apoplexy and tumor size were strong predictors. If the tumor was < 2 cm, 23.5% needed new hormone replacement, and if the tumor was > 3 cm, 54.5% needed new hormone replacement. On the other hand, 39.5% of patients with a preoperative hormone deficiency did not require any long-term replacement. If the tumor was < 2 cm, 53.3% improved, and if the tumor was > 3 cm, 32.7% improved. Factors significantly associated with permanent hormone replacement and improvement besides tumor size and the presence of preoperative hormone deficiencies included hemorrhage on MRI, age, and sex, but these associated factors differed for each axis. CONCLUSIONS: This study highlights the relatively high but balanced rates of hormone loss and improvement after surgical removal of nonhormone-producing adenomas. The size of the tumor, apoplexy, and the patient’s preoperative hormone status are strong predictors of outcome and can be used to estimate hormone function after surgery.

1 January 2025 in Neurophotonics
Verified
Journal Article
Open access
PDF file
JNJames E. Niemeyer
James E. Niemeyer
PLPeijuan Luo
Peijuan Luo
CPCarmen Pons
Carmen Pons
SWShiqiang Wu
Shiqiang Wu
HMHongtao Ma
Hongtao Ma
TSTheodore H. Schwartz
Theodore H. Schwartz
Epilepsy affects ∼1% of the world population at any time1 and shows a lifetime prevalence of 1 in 26 people.2 Despite the development and availability of various anti-seizure medications, more than 35% of epilepsy patients continue to experience seizures,3 leaving surgical options that typically target the seizure onset zone for disconnection, ablation, or neurostimulation. Yet, surgical options targeting this site do not guarantee seizure freedom,4,5 indicating that current concepts of seizure generation, which focus heavily on the seizure onset zone, are not fully adequate to explain its complex biology.6,7 Furthermore, in some circumstances, the seizure focus cannot be targeted because it overlaps with the functional cortex required for normal cognitive processing or behavior. These situations require alternative treatment strategies that do not ablate the seizure focus.

30 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EBErnest J. Bobeff
Ernest J. Bobeff
Bartosz SzmydBartosz Szmyd
Bartosz Szmyd
WMWojciech Młynarski
Wojciech Młynarski
EJEmmanuel Jouanneau
Emmanuel Jouanneau
CACaroline Apra
Caroline Apra
TSTheodore H. Schwartz
Theodore H. Schwartz
Objective: Craniopharyngioma recurrence risk studies comparing gross total resection (GTR) vs. subtotal resection (STR) with radiotherapy (XRT) provide inconclusive or contradictory results. This may be an effect of the small group sizes and diversity in the approaches used. Currently, the endoscopic endonasal approach (EEA) is preferred in craniopharyngioma management. Here, we aimed to perform a meta-analysis comparing recurrence risk after GTR vs. STR plus XRT in patients treated with the EEA regimen. Methods: We performed a systematic literature search of original English language papers on craniopharyngioma management published in the PubMed, Web of Science, and Scopus databases up to 18 October 2023. Eleven articles included data on recurrence rate after EEA: GTR vs. STR with XRT. We extracted the year of publication, number of patients, surgical approach, extent of resection, and follow-up duration. We used meta-analysis for the odds ratio (OR) in fixed and random effects models and Egger’s and Begg’s tests to assess heterogeneity and publication bias. Follow-up duration and time to recurrence were additionally included in Kaplan–Meier curves with log-rank test analysis. Results: We observed a lower recurrence rate in patients after GTR (10%) as compared to STR with XRT (30%), OR = 0.299, p < 0.001. To increase data reliability, we limited our analysis to studies with at least five patients in each subgroup and also observed lower recurrence in patients after GTR (12%) as compared to STR with XRT (27%), OR = 0.376, p = 0.011. Survival analysis confirmed significant differences in recurrence-free survival percentages between these groups (p = 0.008). Conclusions: To date, this is the largest meta-analysis evaluating the recurrence risk in patients undergoing EEA for craniopharyngioma resection, comparing outcomes between those treated with GTR and those treated with STR plus XRT. The results suggest that GTR significantly reduces recurrence risk.

1 April 2025 in Neurosurgical Focus: Video
Verified
Journal Article
Open access
PDF file
NDNader Delavari
Nader Delavari
JLJesse D. Lawrence
Jesse D. Lawrence
JTJonathan Tangsrivimol
Jonathan Tangsrivimol
MTMattia Testa
Mattia Testa
KGKyle J. Godfrey
Kyle J. Godfrey
TSTheodore H. Schwartz
Theodore H. Schwartz
The transorbital craniotomy represents a minimally invasive approach to the mesial structures of the middle fossa. This video depicts the approach to the lateral sphenoid recess in a patient with CSF rhinorrhea secondary to a lateral sphenoid encephalocele. The transorbital approach represents a unique advantage to repairing the lateral sphenoid sinus in comparison to the endoscopic endonasal approach, which requires traversing, and often transecting, the vidian nerve. Following identification of the skull base defect, repair is performed as an underlay with an abdominal fat graft. Following surgery, the patient had no recurrent rhinorrhea. The video can be found here: https://stream.cadmore.media/r10.3171/2025.1.FOCVID24207

10 March 2025 in World Neurosurgery
Verified
Journal Article
Open access
EBErnest J. Bobeff
Ernest J. Bobeff
Bartosz SzmydBartosz Szmyd
Bartosz Szmyd
MSMing Shen
Ming Shen
DJDariusz Jan Jaskólski
Dariusz Jan Jaskólski
TSTheodore H. Schwartz
Theodore H. Schwartz
Craniopharyngioma is a benign, locally invasive tumor of the sellar-suprasellar region. Surgery can be curative but may require sacrifice of the pituitary stalk, which often leads to hypopituitarism. The risk/benefit of this maneuver is not well understood. We performed a systematic English literature search on craniopharyngioma surgery with data on stalk preservation. We used meta-analysis for odds ratio in R software (R Foundation for Statistical Computing, Vienna, Austria). We have also used available raw data for recurrence risk using the Kaplan-Meier curve. Significantly lower recurrence risk was noted in patients in whom the stalk was sacrificed (11% vs. 23%, P = 0.003). This held true in patients after endoscopic endonasal approach (EEA) regardless of the extent of resection (P = 0.001) and in patients with gross total resection after EEA (P = 0.032). Survival analysis confirmed lower recurrence risk in adults with gross total resection after EEA and stalk sacrifice (P = 0.007, log-rank test). In patients with stalk sacrifice, the risk of panhypopituitarism was more than doubled (85% vs. 40%; P < 0.001), as was the risk of somatotrope insufficiency (89% vs. 32%; P < 0.001). Additionally, there was an approximate 30% increase in the risk of hypocortisolemia (94% vs. 62%; P < 0.001), hypothyroidism (96% vs. 59%; P < 0.001), gonadotrope insufficiency (92% vs. 59%; P < 0.001), and diabetes insipidus (80% vs. 55%; P < 0.001). The risk of weight gain was also significantly increased (30% vs. 16%; P = 0.025). Our review indicates that stalk sacrifice is often required to achieve a durable cure in patients with craniopharyngiomas. While stalk sacrifice increases the risk of postoperative endocrinopathy, even if the stalk is preserved, many patients will still become hypopituitary.